Celgosivir - 60 Degree Pharmaceutical Australia
Alternative Names: 6-O-Butanoylcastanospermine; 60P 001; BuCast™; celgosivir hydrochloride; MBI-3253; MDL 28574; MDL 28574A; MX-3253; VIR 222Latest Information Update: 28 May 2024
At a glance
- Originator sanofi-aventis
- Developer 60 Degrees Pharmaceuticals Australia; Carrus Capital Corporation; Duke-NUS Graduate Medical School Singapore; Singapore General Hospital
- Class Antivirals; Indolizines; Small molecules
- Mechanism of Action Alpha-glucosidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Dengue
- Discontinued Hepatitis C; HIV infections
Most Recent Events
- 31 Dec 2023 60 Degrees Pharmaceuticals has patent protection for "Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infections" in Australia, Malaysia, Mexico, Singapore
- 31 Dec 2023 60 Degrees Pharmaceuticals has patent pending for "Methods to treat respiratory infection utilizing castanospermine analogs" in USA
- 31 Dec 2023 60 Degrees Pharmaceuticals has patent pending for "Novel Dosing Regimens Of Celgosivir For The Treatment Of Dengue" in Singapore